Changing the face of COPD care

Media infographic

45 years of experience

GSK has been working to improve the management of respiratory disease for over 45 years. Since 2013 we have gained FDA approval for 4 new medicines for Chronic Obstructive Pulmonary Disease (COPD) making them available in many countries worldwide.

Evolving our COPD portfolio

We are currently investigating a further 6 potential medicines for COPD including:

• An anti-interleukin 5 treatment for severe COPD
• A chemokine receptor 2 antagonist for COPD

Precedent-setting research

Our landmark trials, including two of the largest COPD studies ever undertaken, help inform scientific understanding of COPD management: Salford Lung Study in COPD, SUMMIT, ECLIPSE, IMPACT.

Broadest range of once-daily inhaled COPD treatments

Individual patients have different needs and in COPD these can change over time. We don’t believe in a “one size fits all” approach. We aim to provide the right medicine, for the right patient. We focus on the key areas of patient need in line with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report:

• Treat symptoms
• Reduce risk of exacerbations

We have the broadest range of once-daily treatments for COPD which are delivered using the same type of inhaler. This offers patients the continuity of using the Ellipta inhaler if their treatment needs to be changed.

Beyond medicine development

We have delivered patient support tools and services to further enhance care.

• COPD.com: GSK’s website dedicated to COPD awareness, which offers patients and caregivers resources to learn about COPD. By signing up for the free self-care kit, patients can be better prepared to manage their symptoms.

Date of preparation: August 2017
We are relentless in our work to set precedents in discovering and developing medicines that meet patient needs. This includes innovating in our research to explore emerging scientific concepts:

- **ECLIPSE**: the largest study to investigate subtypes of COPD and predictive markers of its progression.\(^6\)
- **Clinically important deterioration**: reviewing our data to explore whether early treatment can bring greater disease stability by reducing the potential for ‘clinically important deteriorations’ which may represent a worsening of a patient’s COPD.\(^9\)

**Treatable traits**: exploring whether blood eosinophil levels may indicate whether a patient will benefit more from certain types of COPD treatment.\(^7\)

The data and insights from our research, alongside our early phase scientific discovery, give us the potential to continue to transform the way COPD is managed well into the future.

### References (all links accessed August 2017)

1. GSK. 50 years of R&D innovation. Available at: [http://www.gsk.com/media/1287/50-years-of-randd-innovation.pdf](http://www.gsk.com/media/1287/50-years-of-randd-innovation.pdf)


